CD Antigens
Product List
CD274 Human
CD274 Human Recombinant
CD274 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
CD274 Human, Sf9
CD274 Human Recombinant, Sf9
CD274 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 462 amino acids (19-238a.a.) and having a molecular mass of 52.5kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa). CD274 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Sf9, Baculovirus cells.
CD274 Mouse
CD274 Mouse Recombinant
CD274 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Introduction
Key Biological Properties: CD274 is a 40kDa protein that plays a crucial role in immune regulation. It is known for its ability to suppress the adaptive immune system .
Expression Patterns: CD274 is expressed on various cell types, including hematopoietic and non-hematopoietic cells such as T cells, B cells, and various tumor cells .
Tissue Distribution: CD274 is widely distributed in tissues such as the placenta, lung, heart, and various tumor microenvironments .
Primary Biological Functions: CD274 primarily functions as an immune checkpoint molecule. It binds to its receptor, PD-1, on T cells, leading to the inhibition of T cell activation and cytokine production .
Role in Immune Responses: CD274 plays a significant role in maintaining immune homeostasis by preventing autoimmunity and promoting tolerance to self-antigens .
Pathogen Recognition: CD274 is involved in the immune response to infections by modulating the activity of T cells and other immune cells .
Mechanisms with Other Molecules and Cells: CD274 interacts with PD-1 on T cells, delivering inhibitory signals that reduce T cell proliferation and cytokine production .
Binding Partners: The primary binding partner of CD274 is PD-1, but it may also interact with other molecules involved in immune regulation .
Downstream Signaling Cascades: Upon binding to PD-1, CD274 activates downstream signaling pathways that lead to the inhibition of T cell receptor signaling and the promotion of T cell anergy and apoptosis .
Transcriptional Regulation: The expression of CD274 is regulated at the transcriptional level by various factors, including cytokines and transcription factors .
Post-Translational Modifications: CD274 undergoes several post-translational modifications, such as ubiquitination, phosphorylation, glycosylation, and palmitoylation, which affect its stability and function .
Biomedical Research: CD274 is extensively studied in cancer immunotherapy as a target for immune checkpoint inhibitors .
Diagnostic Tools: CD274 expression levels are used as biomarkers for various cancers and are assessed using techniques like immunohistochemistry and flow cytometry .
Therapeutic Strategies: Inhibitors targeting the PD-1/PD-L1 interaction, such as pembrolizumab and nivolumab, are used to enhance anti-tumor immunity in cancer patients .
Development: CD274 is involved in the development of immune tolerance during pregnancy and in the prevention of autoimmune diseases .
Aging and Disease: The expression of CD274 increases in various cancers, contributing to immune evasion by tumor cells. It also plays a role in chronic infections and inflammatory diseases .
